In vivo tumor targetability was evaluated by injecting 50 nmol (2 μmol/kg) of HSA-ZW800-PEG and 100 nmol (4 μmol/kg) of ZW800-PEG into orthotopic and subcutaneous xenograft LLC tumor-bearing mice, respectively. The gene discussed is ALB; the disease is neoplasm.